Xiuyi (Shirley) Dong, CFA, CIPM, has extensive experience in finance and academia, currently serving as the Head of Project Finance Management and Team Lead at CEPI since June 2020. In addition to these roles, Xiuyi is a Guest Lecturer and Lecturer at BI Norwegian Business School, contributing to courses on the CFA Research Challenge and credit markets. Previous positions include Corporate Finance Manager at Cleaves Securities AS, Project Controller at the University of Oslo, Equity Research Analyst at Fondsfinans, and Research Assistant at both Norges Bank and BI Norwegian Business School. Xiuyi holds a Master's degree with Honors in Business and Economics from BI Norwegian Business School, as well as notable credentials from the CFA Institute and other educational institutions.
This person is not in any teams
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net